Serum amyloid A-1 protein (SAA1)

Serum amyloid A-1 protein (SAA1) is a major acute-phase reactant primarily synthesized by hepatocytes in the liver in response to pro-inflammatory cytokines such as IL-1, IL-6, and TNF-alpha [1, 3, 10]. Under physiological conditions, SAA1 circulates at low levels as an apolipoprotein associated with high-density lipoprotein (HDL), where it plays a role in cholesterol transport and lipid metabolism [3, 5, 12]. However, during acute or chronic inflammation, its concentration can increase up to 1,000-fold, leading to its dissociation from HDL and the potential formation of insoluble amyloid fibrils that deposit in organs, causing AA amyloidosis [1, 10, 16]. Beyond its role in amyloidosis, SAA1 acts as a potent chemoattractant for immune cells and a signaling molecule that activates receptors like TLR2, TLR4, and FPR2 to amplify the inflammatory cascade [3, 11, 13]. In the context of disease, elevated SAA1 levels are strongly associated with chronic inflammatory conditions like rheumatoid arthritis, cardiovascular risks such as atherosclerosis, and the progression of various cancers, including acute myeloid leukemia [1, 13, 21, 22]. Therapeutic targeting of SAA1 is an active area of research, with strategies including antisense oligonucleotides (e.g., nL-SAA1-01) to silence its gene expression, monoclonal antibodies to neutralize its activity, and small peptidomimetics to inhibit its aggregation into toxic fibrils [1, 2, 20, 25]. Additionally, indirect inhibition through IL-6 receptor antagonists like tocilizumab is clinically used to reduce SAA1 production in inflammatory disorders [4, 17]. SAA1 remains a critical biomarker for monitoring disease severity and therapeutic efficacy in conditions ranging from traumatic brain injury to hyper-inflammatory syndromes like COVID-19 [4, 14, 15].

Other names

SAASAA1PIG4TP53I4Amyloid fibril protein AAAmyloid protein ASerum amyloid A1 cluster

Inhibition of SAA1 protein synthesis via antisense oligonucleotides (ASOs); neutralization of circulating SAA1 using monoclonal antibodies; prevention of SAA1 fibril formation and aggregation through peptidomimetics; indirect reduction of SAA1 production by inhibiting upstream pro-inflammatory cytokines like IL-6; and modulation of SAA1-mediated signaling by antagonizing receptors such as TLR2, TLR4, and FPR2.